These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 36820511

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, Giske CG, Lodise T, Sanguinetti M, Piddock LJV, Franceschi F, Ellis S, Carrara E, Savoldi A, Tacconelli E.
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
    Quale J, Shah N, Kelly P, Babu E, Backer M, Rosas-Garcia G, Salamera J, George A, Bratu S, Landman D.
    Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
    [Abstract] [Full Text] [Related]

  • 5. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H, Poulakou G.
    Drugs; 2009 Oct 01; 69(14):1879-901. PubMed ID: 19747006
    [Abstract] [Full Text] [Related]

  • 6. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
    Doymaz MZ, Karaaslan E.
    Infect Dis (Lond); 2019 Sep 01; 51(9):676-682. PubMed ID: 31298061
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
    Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Wang H.
    J Antimicrob Chemother; 2020 Sep 01; 75(9):2609-2615. PubMed ID: 32591806
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
    Clock SA, Tabibi S, Alba L, Kubin CJ, Whittier S, Saiman L.
    Diagn Microbiol Infect Dis; 2013 Jul 01; 76(3):343-6. PubMed ID: 23601454
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Colistin and polymyxin B in critical care.
    Michalopoulos A, Falagas ME.
    Crit Care Clin; 2008 Apr 01; 24(2):377-91, x. PubMed ID: 18361952
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
    Papadopoulos A, Ribera A, Mavrogenis AF, Rodriguez-Pardo D, Bonnet E, Salles MJ, Dolores Del Toro M, Nguyen S, Blanco-García A, Skaliczki G, Soriano A, Benito N, Petersdorf S, Pasticci MB, Tattevin P, Tufan ZK, Chan M, O'Connell N, Pantazis N, Kyprianou A, Pigrau C, Megaloikonomos PD, Senneville E, Ariza J, Papagelopoulos PJ, Giannitsioti E, ESCMID Study Group for Implant-Associated Infections (ESGIAI).
    Int J Antimicrob Agents; 2019 Mar 01; 53(3):294-301. PubMed ID: 30395988
    [Abstract] [Full Text] [Related]

  • 13. Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria.
    Wang Y, Feng J, Yu J, Wen L, Chen L, An H, Xiao W, Zhang B, Feng H, Zhou M, Jiang Z.
    Ann Clin Microbiol Antimicrob; 2024 Jul 04; 23(1):60. PubMed ID: 38965559
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical Use of Polymyxin B.
    Rigatto MH, Falci DR, Zavascki AP.
    Adv Exp Med Biol; 2019 Jul 04; 1145():197-218. PubMed ID: 31364080
    [Abstract] [Full Text] [Related]

  • 16. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S, Kritsotakis EI, Gikas A.
    Infection; 2020 Dec 04; 48(6):835-851. PubMed ID: 32875545
    [Abstract] [Full Text] [Related]

  • 17. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD, Suresh K.
    Med J Malaysia; 2018 Oct 04; 73(5):351-359. PubMed ID: 30350826
    [Abstract] [Full Text] [Related]

  • 18. Polymyxins: To Combine or Not to Combine?
    Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA.
    Antibiotics (Basel); 2019 Apr 10; 8(2):. PubMed ID: 30974813
    [Abstract] [Full Text] [Related]

  • 19. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
    Zimmerman SM, Lafontaine AJ, Herrera CM, Mclean AB, Trent MS.
    Antimicrob Agents Chemother; 2020 Feb 21; 64(3):. PubMed ID: 31844003
    [Abstract] [Full Text] [Related]

  • 20. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B.
    Eur J Clin Microbiol Infect Dis; 2021 Mar 21; 40(3):461-475. PubMed ID: 33009595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.